Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies - PubMed (original) (raw)
Review
. 2000 Dec 27;19(56):6584-93.
doi: 10.1038/sj.onc.1204146.
Affiliations
- PMID: 11426643
- DOI: 10.1038/sj.onc.1204146
Review
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies
S M Sebti et al. Oncogene. 2000.
Abstract
In 1990, more than 10 years after the discovery that the low molecular weight GTPase Ras is a major contributor to human cancer, farnesylation, a lipid posttranslational modification required for the cancer-causing activity of Ras, emerged as a major target for the development of novel anticancer agents. However, it took only 5 years from 1993, when the first farnesyltransferase inhibitors (FTIs) were reported, to 1998 when results from the first phase I clinical trials were described. This rapid progress was due to the demonstration of outstanding antitumor activity and lack of toxicity of FTIs in preclinical models. Although, many FTIs are currently in phase H and at least one is in phase III clinical trial, the mechanism of FTI antitumor activity is not known. In this review a brief summary of the development of FTIs as antitumor agents will be given. The focus of the review will be on important mechanistic and bench-to-bedside translational issues. Among the issues that will be addressed are: evidence for and against inhibition of the prenylation of Ras and RhoB proteins in the mechanism of action of FTIs; implications of the alternative prenylation of K-Ras by geranylgeranyl-transferase I (when FTase is inhibited) in cancer therapy; GGTase I inhibitors (GGTIs) as antitumor agents; effects of FTIs and GGTIs on cell cycle machinery and progression and potential mechanisms by which FTIs and GGTIs induce apoptosis in human cancer cells. A thorough discussion about bench-to-bedside issues relating to hypothesis-driven clinical trials with proof-of-principle in man will also be included. This section will cover issues relating to whether the biochemical target (FTase) is inhibited and the level of inhibition of FTase required for clinical response; are signaling pathways such as H-Ras/PI3K/Akt and/or K-Ras/Raf/MEK/Erk relevant biological readouts?; is Ras (particularly N-Ras and H-Ras) mutation status a good predictor of clinical response?; in phase I trials should effective biological dose, not maximally tolerated dose, be used to determine phase II dose?; and finally, in phase II/III trials what are the most appropriate clinical end points for anti-signaling molecules such as FTIs? Parts of this topic have been recently reviewed (Sebti and Hamilton, 2000c).
Similar articles
- Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Sebti SM, Hamilton AD. Sebti SM, et al. Expert Opin Investig Drugs. 2000 Dec;9(12):2767-82. doi: 10.1517/13543784.9.12.2767. Expert Opin Investig Drugs. 2000. PMID: 11093352 Review. - Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE. Lobell RB, et al. Cancer Res. 2001 Dec 15;61(24):8758-68. Cancer Res. 2001. PMID: 11751396 - Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K, Hamilton AD, Sebti SM. Zhu K, et al. Curr Opin Investig Drugs. 2003 Dec;4(12):1428-35. Curr Opin Investig Drugs. 2003. PMID: 14763128 Review. - Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF, Prendergast GC. Lebowitz PF, et al. Oncogene. 1998 Sep 17;17(11 Reviews):1439-45. doi: 10.1038/sj.onc.1202175. Oncogene. 1998. PMID: 9779989 Review.
Cited by
- Library Screening, In Vivo Confirmation, and Structural and Bioinformatic Analysis of Pentapeptide Sequences as Substrates for Protein Farnesyltransferase.
Schey GL, Hildebrandt ER, Wang Y, Diwan S, Passetti HA, Potts GW, Sprague-Getsy AM, Leoni ER, Kuebler TS, Sham YY, Hougland JL, Beese LS, Schmidt WK, Distefano MD. Schey GL, et al. Int J Mol Sci. 2024 May 13;25(10):5324. doi: 10.3390/ijms25105324. Int J Mol Sci. 2024. PMID: 38791363 Free PMC article. - Small-Molecule Inhibition of KRAS through Conformational Selection.
Pagba CV, Gupta AK, Gorfe AA. Pagba CV, et al. ACS Omega. 2023 Aug 18;8(34):31419-31426. doi: 10.1021/acsomega.3c04013. eCollection 2023 Aug 29. ACS Omega. 2023. PMID: 37663463 Free PMC article. - Protein Farnesylation on Nasopharyngeal Carcinoma, Molecular Background and Its Potential as a Therapeutic Target.
Kobayashi E, Kondo S, Dochi H, Moriyama-Kita M, Hirai N, Komori T, Ueno T, Nakanishi Y, Hatano M, Endo K, Sugimoto H, Wakisaka N, Yoshizaki T. Kobayashi E, et al. Cancers (Basel). 2022 Jun 8;14(12):2826. doi: 10.3390/cancers14122826. Cancers (Basel). 2022. PMID: 35740492 Free PMC article. Review. - Therapeutic Targeting of Rab GTPases: Relevance for Alzheimer's Disease.
Jordan KL, Koss DJ, Outeiro TF, Giorgini F. Jordan KL, et al. Biomedicines. 2022 May 16;10(5):1141. doi: 10.3390/biomedicines10051141. Biomedicines. 2022. PMID: 35625878 Free PMC article. Review. - Targeting mutations in cancer.
Waarts MR, Stonestrom AJ, Park YC, Levine RL. Waarts MR, et al. J Clin Invest. 2022 Apr 15;132(8):e154943. doi: 10.1172/JCI154943. J Clin Invest. 2022. PMID: 35426374 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous